Mizuho Securities Sticks to Their Buy Rating for Aerie Pharma (AERI)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) on June 21 and set a price target of $77. The company’s shares closed on Friday at $30.91, close to its 52-week low of $30.12.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 9.8% and a 42.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $75.43, implying a 144.0% upside from current levels. In a report issued on June 11, Canaccord Genuity also maintained a Buy rating on the stock with a $56 price target.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $47.95 million. In comparison, last year the company had a GAAP net loss of $40.7 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.